Skip to main content
. 2008 Apr 15;6:17. doi: 10.1186/1479-5876-6-17

Figure 3.

Figure 3

CD131 expression following IVS with Flu M1:58-66 peptide. Expression of CD131 (GMCSF receptor β chain) in Flu M1:58-66-activated (tHLA/Flu +) and convivial (tHLA/Flu-) CTLs (corresponding to R4 and R7 in Figure 1) after 6 (A) and 12 (B) days of IVS of HLA-A*0201 expressing PBMCs in the presence of 300 IU/ml of IL-2; C – Fold increase (FI) of HLA-A*0201 PBMCs exposed to IVS with Flu M1:58-66 peptide (Flu) plus exogenous administration every other day of IL-2 (300 IU/ml), GMCSF (1,000 U/ml), IFN-γ (500 IU/ml) or a combination of them for 6 (white bars) or 12 (black bars) days. Data are presented as average ± standard error from the mean of 5 experiments performed in PBMCs from 5 different donors; * and ** = paired Student t test p-value ≤ 0.05 and ≤ 0.01 respectively between comparing FI in individuals experimental groups with the FI in respective PBMC populations stimulated only with Flu; The difference in significance between Flu+IL-2+GMCSF FI at day 12 and that of Flu+IL-2 and Flu+IL-2+IFN-γ are outlined specifically in the graph.